Aiming at '$12B Opportunity,' Illumina to Expand Sales Presence, Invest in Reproductive Health | GenomeWeb

Illumina plans to expand its sales presence both at home and abroad as decreasing prices for its microarray and sequencing products allow it to reach new customers, according to a company executive.

Christian Henry, general manager of Illumina's Genomics Solutions business, provided an update on the company at the RW Baird Growth Stock Conference, held last week in Chicago.

According to Henry, whose remarks were webcast, Illumina will "add significantly" to its sales force this year to reach customers in emerging markets.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.